Paolo Di Giorgio is the Chief Executive Officer and Managing Director of Angelini Ventures, the corporate venture arm of Angelini Industries. The fund’s recent investments include a participation in Argobio, a european start-up studio, the co-founding of the Angelini Lumira Bioscience Fund, a fund that invests in early stage CNS companies in north America, and an investment in Pretzel Therapeutics, a company developing innovative therapeutics for mitochondrial disorders.
Paolo is a life sciences executive with over 15 years of experience in venture capital, R&D, external innovation and business development at Merck, Novartis and Angelini Pharma. Originally a neuroscientist by training, he has led global teams on several projects in different therapeutic areas such as neuroscience, pain, rare diseases, anti-infectives, oncology, and metabolic disorders.
During his Ph.D and post-doctoral studies at Harvard University and at the Salk Institute for Biological Studies, Paolo pioneered a novel method to study neurodegenerative diseases using stem cell-derived neurons. Paolo has also completed an executive MBA program at IE Business School in Madrid, Spain.
He is currently leading the External Innovation and Corporate Ventures groups of Angelini Pharma: his team is managing integrated drug discovery programs, conducting search and evaluation of companies operating in the CNS and rare diseases space, investing in funds and start-ups.
Their recent investments includes: a participation in Argobio, a European venture studio based in Paris; the co-founding of the Angelini Lumira Bioscience Fund (ALBF), a fund focused in early stage CNS/rare diseases companies, managed by Lumira Ventures; and an investment in Pretzel Therapeutics.